| Gender Preference | None |
| Age Group | 18 - 99 years |
| Research Start Date | August 9, 2012 |
| Research End Date | August 9, 2022 |
| Principal Investigator | Raymond Hohl, MD |
| Description | Participants in this research study have been diagnosed with a type of multiple myeloma that has grown or spread and cannot be cured by surgery, radiation or any other conventional therapies. The purpose of this research study is to identify the side effects of the study drug, ALT-801, in patients with multiple myeloma, and to find out how safe it is, and how well it is tolerated. Investigators also wish to find out if the study drug can slow the progression of the disease and/or reduce the size of the tumors. |
| Contact Info | Karen Parrott, 319-353-6347 |
| Keywords | span itemProp='description'>ALT-801 ; cancer ; hohl ; IRB#201202504 ; multiple myeloma ; phase 1 ; phase 2 ; phase I ; phase II ; |